{"uri": "eng-9418353", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Committee_for_Medicinal_Products_for_Human_Use", "type": "wiki", "score": 100, "label": {"eng": "Committee for Medicinal Products for Human Use"}}, {"uri": "http://en.wikipedia.org/wiki/Bevacizumab", "type": "wiki", "score": 95, "label": {"eng": "Bevacizumab"}}, {"uri": "http://en.wikipedia.org/wiki/Ophthalmology", "type": "wiki", "score": 79, "label": {"eng": "Ophthalmology"}}, {"uri": "http://en.wikipedia.org/wiki/European_Union", "type": "loc", "score": 71, "label": {"eng": "European Union"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/European_Medicines_Agency", "type": "wiki", "score": 64, "label": {"eng": "European Medicines Agency"}}, {"uri": "http://en.wikipedia.org/wiki/Macular_degeneration", "type": "wiki", "score": 62, "label": {"eng": "Macular degeneration"}}, {"uri": "http://en.wikipedia.org/wiki/AMD", "type": "wiki", "score": 60, "label": {"eng": "AMD"}}, {"uri": "http://en.wikipedia.org/wiki/Retina", "type": "wiki", "score": 58, "label": {"eng": "Retina"}}, {"uri": "http://en.wikipedia.org/wiki/European_Commission", "type": "org", "score": 49, "label": {"eng": "European Commission"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 45, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/Europe", "type": "loc", "score": 44, "label": {"eng": "Europe"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 43, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor", "type": "wiki", "score": 43, "label": {"eng": "Vascular endothelial growth factor"}}, {"uri": "http://en.wikipedia.org/wiki/Gamma_ray", "type": "wiki", "score": 38, "label": {"eng": "Gamma ray"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 37, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 36, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 34, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Endothelium", "type": "wiki", "score": 28, "label": {"eng": "Endothelium"}}, {"uri": "http://en.wikipedia.org/wiki/European_Economic_Area", "type": "loc", "score": 25, "label": {"eng": "European Economic Area"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Intravitreal_administration", "type": "wiki", "score": 23, "label": {"eng": "Intravitreal administration"}}, {"uri": "http://en.wikipedia.org/wiki/Monoclonal_antibody", "type": "wiki", "score": 22, "label": {"eng": "Monoclonal antibody"}}, {"uri": "http://en.wikipedia.org/wiki/United_States", "type": "loc", "score": 19, "label": {"eng": "United States"}, "location": {"type": "country", "label": {"eng": "United States"}}}, {"uri": "http://en.wikipedia.org/wiki/Norway", "type": "loc", "score": 19, "label": {"eng": "Norway"}, "location": {"type": "country", "label": {"eng": "Norway"}}}, {"uri": "http://en.wikipedia.org/wiki/Liechtenstein", "type": "loc", "score": 19, "label": {"eng": "Liechtenstein"}, "location": {"type": "country", "label": {"eng": "Liechtenstein"}}}, {"uri": "http://en.wikipedia.org/wiki/Iceland", "type": "loc", "score": 19, "label": {"eng": "Iceland"}, "location": {"type": "country", "label": {"eng": "Iceland"}}}, {"uri": "http://en.wikipedia.org/wiki/Cell_proliferation", "type": "wiki", "score": 16, "label": {"eng": "Cell proliferation"}}, {"uri": "http://en.wikipedia.org/wiki/Angiogenesis", "type": "wiki", "score": 16, "label": {"eng": "Angiogenesis"}}, {"uri": "http://en.wikipedia.org/wiki/Potency_(pharmacology)", "type": "wiki", "score": 16, "label": {"eng": "Potency (pharmacology)"}}], "eventDate": "2024-03-22", "totalArticleCount": 8, "title": {"eng": "Outlook Therapeutics nears EU nod for eye treatment By Investing.com"}, "summary": {"eng": "ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its investigational ophthalmic formulation of bevacizumab, known as ONS-5010/LYTENAVA\u2122. This endorsement is a crucial step towards potential European Commission (EC) authorization for the treatment of wet age-related macular degeneration (wet AMD (NASDAQ:AMD)).\n\nThe CHMP's favorable opinion is based on data from th"}, "location": null, "categories": [{"uri": "dmoz/Society/Government/Multilateral", "label": "dmoz/Society/Government/Multilateral", "wgt": 71}, {"uri": "dmoz/Society/Issues/Health", "label": "dmoz/Society/Issues/Health", "wgt": 100}, {"uri": "dmoz/Health/Specific_Substances/Tobacco", "label": "dmoz/Health/Specific Substances/Tobacco", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 66}], "articleCounts": {"eng": 8}, "sentiment": 0.4431372549019608, "wgt": 448761600, "relevance": 1}